Travere Therapeutics (NASDAQ:TVTX) Announces Earnings Results

Travere Therapeutics (NASDAQ:TVTX) issued its quarterly earnings results on Monday. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.45), Zacks reports. The business had revenue of $224.56 million for the quarter, compared to analyst estimates of $195.29 million. Travere Therapeutics had a negative return on equity of 55.15% and a negative net margin of 7.35%. The business’s revenue was up 36.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.28 earnings per share.

Here are the key takeaways from Travere Therapeutics’ conference call:

• Positive Sentiment: FILSPARI U.S. net product sales rose approximately 120% year over year to $200.2 million in Q3, surpassing $200 million for the first time. Management cited strong demand, prescription conversion, and patient persistence across IgA nephropathy and the newly approved FSGS indication.
• Positive Sentiment: FSGS launch momentum was strong, with rapid conversion to paid prescriptions, expanding prescriber adoption, and payer coverage progressing well. Travere said roughly 40% of first-time FSGS prescribers in the quarter were new to FILSPARI, supporting its confidence in achieving or exceeding $3 billion in annual sales by 2033.
• Negative Sentiment: Q3 FILSPARI sales benefited by approximately $8 million from elevated specialty-pharmacy inventory, which is expected to reverse in Q4 as distributors return to normal stock levels. The company also expects higher discounts, with full-year gross-to-net deductions in the mid-20% range.
• Positive Sentiment: The pipeline advanced, with pegtibatinase HARMONY enrollment progressing toward top-line results in the second half of 2027 and civorebrutinib moving toward a U.S. IND submission by year-end. Travere also reported patent progress for FILSPARI that could extend protection in IgA nephropathy and FSGS into 2037.
• Neutral Sentiment: CEO Eric Dube plans to step down in December, with Bradley expected to join as his successor on December 1. Management characterized the transition as occurring from a position of strength, though leadership changes remain an execution consideration for investors.

Travere Therapeutics Price Performance

TVTX stock opened at $49.26 on Tuesday. The company has a debt-to-equity ratio of 24.58, a current ratio of 4.05 and a quick ratio of 3.99. The company’s 50-day moving average is $58.73 and its 200-day moving average is $46.56. The stock has a market capitalization of $4.64 billion, a PE ratio of -107.08 and a beta of 1.13. Travere Therapeutics has a 1 year low of $22.59 and a 1 year high of $68.73.

Insiders Place Their Bets

In related news, CEO Eric Dube sold 243,735 shares of the company’s stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $53.82, for a total transaction of $13,117,817.70. Following the transaction, the chief executive officer directly owned 432,886 shares of the company’s stock, valued at approximately $23,297,924.52. This represents a 36.02% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Elizabeth Reed sold 37,500 shares of the company’s stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $62.34, for a total value of $2,337,750.00. Following the transaction, the insider directly owned 105,389 shares in the company, valued at approximately $6,569,950.26. This trade represents a 26.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,294,029 shares of company stock worth $79,454,261 over the last three months. Insiders own 4.44% of the company’s stock.

Key Travere Therapeutics News

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: Third-quarter revenue increased 36.2% year over year to approximately $224.6 million, exceeding the roughly $195.3 million analyst consensus. FILSPARI net product sales reached $200 million, reflecting continued expansion in IgA nephropathy and focal segmental glomerulosclerosis. Travere Therapeutics Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Management described the quarter as another period of significant growth and emphasized continued execution in expanding FILSPARI’s commercial reach. The revenue performance and product momentum support the longer-term growth outlook. Travere Therapeutics Q3 2026 Earnings Call Transcript
• Neutral Sentiment: Some valuation commentary argues that TVTX could be approximately 34% undervalued based on its growth prospects and expected future cash flows. However, this is an analyst valuation view rather than a change in the company’s operating results. Why Travere Therapeutics Could Be Undervalued
• Negative Sentiment: Travere reported a third-quarter GAAP loss of $0.55 per share, substantially worse than consensus estimates for a loss of approximately $0.10–$0.25 per share, and compared with earnings of $0.28 per share a year earlier. The company also posted a negative net margin and negative return on equity. Travere Therapeutics Reports Q3 Loss, Tops Revenue Estimates

Analyst Ratings Changes

Several equities research analysts recently commented on TVTX shares. Piper Sandler restated an “overweight” rating on shares of Travere Therapeutics in a research report on Monday, August 17th. Guggenheim lifted their target price on Travere Therapeutics from $75.00 to $89.00 and gave the stock a “buy” rating in a report on Thursday, September 24th. Zacks Research cut Travere Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 20th. Wedbush restated an “outperform” rating and set a $76.00 price target on shares of Travere Therapeutics in a report on Tuesday, September 22nd. Finally, Citigroup raised their price objective on shares of Travere Therapeutics from $70.00 to $85.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Ten equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Travere Therapeutics has an average rating of “Moderate Buy” and an average price target of $69.50.

About Travere Therapeutics

Travere Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases, with an emphasis on serious kidney conditions. The company’s work centers on addressing diseases with limited treatment options and improving outcomes for patients with progressive renal disorders.

Travere’s lead commercial product is FILSPARI (sparsentan), an oral treatment for adults with primary immunoglobulin A nephropathy (IgA nephropathy) who are at risk of disease progression.